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Summary
C1 inhibitor deficiency is a rare disorder manifesting with recurrent
attacks of disabling and potentially life-threatening angioedema. Here we
present an updated 2014 United Kingdom consensus document for the
management of C1 inhibitor-deficient patients, representing a joint
venture between the United Kingdom Primary Immunodeficiency
Network and Hereditary Angioedema UK. To develop the consensus, we
assembled a multi-disciplinary steering group of clinicians, nurses and a
patient representative. This steering group first met in 2012, developing a
total of 48 recommendations across 11 themes. The statements were
distributed to relevant clinicians and a representative group of patients to
be scored for agreement on a Likert scale. All 48 statements achieved a
high degree of consensus, indicating strong alignment of opinion. The
recommendations have evolved significantly since the 2005 document,
with particularly notable developments including an improved evidence
base to guide dosing and indications for acute treatment, greater
emphasis on home therapy for acute attacks and a strong focus on service
organization.
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Introduction
C1 esterase inhibitor deficiency (C1 inhibitor deficiency) is
a rare disorder that may be genetic (hereditary angioedema,
HAE) [1] or less commonly acquired (acquired angio-
edema, AAE) [2]. The disease has an estimated prevalence
of 1 : 50 000; any ethnic group may be affected, and many
cases are undiagnosed [3–5]. C1 inhibitor deficiency mani-
fests with episodic attacks of bradykinin-mediated localized
subcutaneous and/or submucosal swellings, with a predilec-
tion for the face, extremities, gut, genitals, oropharynx and
upper respiratory tract [6]. Abdominal attacks are
extremely painful and disruptive, while laryngeal swelling is
life-threatening and accounts for the very significant life-
time mortality reported from historical data [6–8].
The evidence base for disease management has expanded
significantly since the first UK consensus document was
published in 2005 [9]. For acute therapy, extensive data are
now available for two new drugs that target the bradykinin
pathway [10–17], for two established plasma-derived C1
inhibitor replacement products [18–20] and for a novel
recombinant C1 inhibitor concentrate product [21–23].
Further evidence supports the use of home therapy for
acute attacks, an approach with clear benefits for patients
and the wider health economy [24–28]. The effectiveness of
regular C1 inhibitor concentrate injections for long-term
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prophylaxis is now established more firmly, presenting an
alternative to attenuated androgens for selected patients
[19,29]. In parallel with these advances in medical manage-
ment, focused research efforts have revolutionized our
understanding of the impact of C1 inhibitor deficiency on
the physical, emotional and economic health of patients
and their families [5,30–34], thus informing the application
of this improved evidence base.
A number of documents have translated these data
into evidence-based guidelines [24,35–41], but none fully
reflect the priorities and organization of services for C1
inhibitor-deficient patients in the United Kingdom. With
these considerations in mind, the United Kingdom Pri-
mary Immunodeficiency Network (UK PIN – a cross-
disciplinary professional association) and the patient
group Hereditary Angioedema UK (HAE UK) jointly
commissioned this project to update the 2005 UK con-
sensus document.
Several considerations are particularly pertinent to the
context of this document. The UK National Health Serv-
ice (NHS) is dealing with unprecedented financial pres-
sure, and while successive governments have continued to
pledge commitment to a health-care system that is free at
the point of demand, traditional hospital-based models of
health care are unlikely to be affordable for the United
Kingdom in the long term. Recent government initiatives
have focused on community and patient-centred ‘inte-
grated’ care, both as a means to ensure long-term afford-
ability and to improve social and medical outcomes [42].
There has also been increased awareness of more rare dis-
eases, with the needs of affected patients recognized in
UK initiatives [43]. Finally, there is a perception that the
provision of specialist services for C1 inhibitor-deficient
patients varies geographically [44], with possible underly-
ing factors including the availability of funding for high-
cost drugs and the location of major centres of expertise.
In England, these considerations have contributed to
radical reform of specialist services for patients with C1
inhibitor deficiency and other rare diseases: centralized
funding has been devolved to NHS England, with the com-
missioning specification encouraging expert patient-
centred care, coordinated by specialist centres that fulfil
predefined standards [45]. The organization of services in
other UK nations differs: in Wales, all patients access serv-
ices at the Immunodeficiency Centre in Cardiff, with cen-
trally commissioned resources transferred from Health
Boards; in Scotland, patients access local services or travel
across Unitary Health Board areas where this is not possi-
ble, with high-cost medicines accessed through a Pharmacy
Board structure overseen by the Scottish Medicines Com-
mittee; in Northern Ireland, services are centralized to the
Regional Immunology Service in Belfast, with a local pro-
cess for the approval of high-cost drugs.
It was not felt appropriate to replicate the excellent
work that has produced a plethora of recent evidence-
based guidelines in the field of C1 inhibitor deficiency
[24,35–41]. Instead, we sought to produce a UK-specific
document that is complementary to existing guidelines.
To achieve this aim, the guidelines have been produced
using the Delphi method, a structured process that aims
to produce consensus among a group of experts. We
report here the consensus process and statements that
were ultimately approved. This document, together with
standards for specialist services issued by UK PIN [46],
provides a framework for the management of C1
inhibitor-deficient patients in the United Kingdom.
Methods
The research design for the consensus was based on the
Delphi method: respondents are presented with a series
of statements, each of which is scored for agreement
using a four-point Likert scale, as follows: strongly agree,
tend to agree, tend to disagree, strongly disagree. Follow-
ing the first round of responses, any statements consid-
ered contentious (typically less than 66% of respondents
agree) may be reviewed, with the final list of statements
representing the consensus.
The questionnaire was developed by the HAE Consensus
Steering Group, which included a patient representative,
eight physicians with a specialist interest in the disease and
three specialist nurses. Throughout a day of discussion on
26 September 2012, the Steering Group agreed a total of 48
consensus statements across 11 themes. When developing
these statements, the Steering Group considered develop-
ments in the evidence base, published guidelines for
specialist services [45,46] and personal experiences. The
statements were incorporated into a consensus question-
naire, with a slightly modified plain-language version
generated for patient use. Questionnaires were sent to all
UK-based physicians and specialist nurses known to be
involved in the management of C1 inhibitor-deficient
patients, and additionally to the membership of key profes-
sional organizations (Table 1). Patients were invited to
express their opinion by HAE UK. Two subsequent oppor-
tunities to complete the questionnaire were provided by
Table 1. Professional societies invited to participate in the consensus
process.
Professional organization
Association of Clinical Pathologists
British Association of Dermatologists
British Dental Association
British Society for Allergy and Clinical Immunology
British Society for Immunology
College of Emergency Medicine
Institute of Biomedical Science
Royal College of Anaesthetists
Royal College of General Practioners
Royal College of Pathologists
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electronic mail, and additional paper copies were distrib-
uted at professional and academic meetings.
The process was facilitated by Triducive Ltd, who col-
lated the anonymized data for consideration by the panel.
A second meeting was held on 18 November 2013 to dis-
cuss the findings and approve the consensus statements.
Results
Ninety-one health-care workers (51 consultant immunolo-
gists and/or allergists, 10 specialist registrars training in
clinical immunology or allergy, 14 immunology specialist
nurses, 16 other or unknown designations) responded, rep-
resenting the majority of health-care professionals who care
actively for this patient group. A total of 36 patients with
C1 inhibitor deficiency responded. All four nations within
the United Kingdom were represented among respondents.
The consensus statements are listed in Table 2. A high
degree of consensus was obtained during the first round,
with more than 90% of respondents indicating ‘strongly
agree’ or ‘tend to agree’ to all the statements and few absten-
tions (Supporting information, Table S1). As all statements
achieved consensus in excess of 90%, no iterative amend-
ment was required. Consensus was highest among patient
respondents, with more than 97% agreement to all state-
ments. Among health-care workers, agreement of >90% was
achieved in response to 47 of 48 questions; statement 20
– concerning use of anti-fibrinolytics in prophylaxis –
achieved 88.8% agreement. In general, most statements eli-
cited ‘strong agreement’, with ‘tend to disagree’ and ‘strongly
disagree’ rarely observed. Consensus remained extremely
high when analysed by occupation or speciality, although
small numbers limit the interpretation of subgroup analysis.
Alignment of these statements to accreditation standards for
specialist centres published by UK PIN is described in Sup-
porting information, Table S2.
A facility for freetext comments was utilized by a
minority of respondents to comment on the statements
and study process: one respondent criticized the docu-
ment for being too ‘centralist’ and another suggested that
the definition of ‘specialist centre’ should be kept flexible
enough to allow for different models of care. Some ques-
tions (for example, concerning children or new medica-
tions) were indicated as inappropriate for those without
specific expertise. We note that some respondents did not
comment on all statements, presumably denoting lack of
expertise or opinion with regard to a particular statement
(see Supporting information, Table S1).
Discussion
We present here an updated UK consensus for the man-
agement of patients with C1 inhibitor deficiency. The
consensus was developed using the Delphi method, an
established process for the collation of opinion from a
group of experts. According to this process, respondents
indicate agreement with statements in rounds; after each
round, facilitators collate and anonymize the responses to
guide amendment of the statements for future rounds.
The process is completed when predefined levels of con-
sensus are reached. This method was pursued in order to
produce guidelines that are complementary to recent
publications [24,35–41] and with an emphasis on UK
services.
The consensus has evolved significantly since the previ-
ous 2005 UK document. A particularly important develop-
ment is an improved evidence base to guide the
management of acute attacks. The dosing of C1 inhibitor
concentrate (statement 17) was particularly emphasized,
given the availability of guidance from robust trial data
[18–21]. However, clinical experience suggests that individ-
ualized dosing is appropriate, including higher doses where
treatment is delayed and lower doses when treatment is
immediately available (statement 18). In keeping with other
recent guidelines [24,35–41], the document supports the
wider use of acute treatment for disabling attacks (state-
ment 3) rather than limiting treatment to severe episodes.
Statement 2 (treatment of HAE should follow international
guidance and standards, while considering the resources
available in the United Kingdom) and statement 12
(patients should take medication according to clinical need
rather than financial considerations) could perhaps be con-
sidered to conflict. We would emphasize, however, that as
currently worded, the consensus for statements 2 and 3
does not mandate treatment for all attacks – rather, less
serious attacks are considered to be potentially treatable.
Consideration of treatment costs will form part of the deci-
sion process when weighing up whether or not symptoms
are sufficiently disabling to warrant therapy within the
parameters of statement 12. Regarding long-term prophy-
laxis, the value of closely monitored androgens with appro-
priate monitoring is endorsed (statements 21–25). A
greater emphasis is placed on long-term prophylaxis with
C1 inhibitor concentrate (statement 27), reflecting an
improved evidence base [19,29] and increased experience
among clinicians and patients. Long-term prophylaxis with
tranexamic acid continues to be supported in the paediatric
setting where options are limited (statement 46). A more
guarded statement was supported (with 88.9% consensus
among health-care workers) for the general use of this agent
for long-term prophylaxis (statement 20); this was the only
statement to achieve consensus below 90%, reflecting a
weak evidence base and mixed practice.
Saule and colleagues published an observational series
including 16 women with hereditary angioedema, describ-
ing modest benefit from progestagens in long-term prophy-
laxis [47]. The authors recommended either desogestrel
75 mg daily (Cerazette), medroxyprogesterone acetate
(Depo-Provera) or norethisterone 10 mg daily. The latter
two options provide a higher dose and possibly a higher
2014 UK HAE consensus
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Table 2. 2014 C1 inhibitor deficiency consensus statements.
A: Treatment objectives
1. Each C1 inhibitor-deficient patient should be able to manage his or her symptoms proactively in such a way that they maintain personal safety
and minimal disruption in living a healthy and productive life
2. Treatment of HAE should follow international guidance and standards, whilst considering the resources available in the UK
3. All disabling attacks irrespective of location are eligible for treatment as soon as they are clearly recognized
4. Patient self-treatment is the ideal service model in line with government policy
B: Access to expertise
5. Every patient should be under the supervision of a specialist hub centre for HAE, either directly or via a spoke centre
6. A specialist centre has appropriate resources and a sufficient cohort of patients to maintain appropriate expertise in the treatment of HAE
7. Informative educational literature and support should be made available to every HAE patient
8. People with suspected HAE need to have access to a specialist centre expert
9. Every patient (including children) should be offered the option of home administration with appropriate monitoring, training and
governance
C: Access to medication
10. Every patient should hold a safe quantity (minimum of one) of acute treatment doses at home dependent on individual needs
11. It is important that arrangements are in place to facilitate speedy replacement of acute attack medication after use so that the patient may
proactively manage their symptoms safely with minimum disruption to living a healthy and productive life
12. Patient should take their medication according to clinical need rather than financial considerations
D: Acute treatment
13. Plasma-derived C1 inhibitors (Berinert, Cinryze), recombinant C1 inhibitor (Ruconest) and Icatibant (Firazyr) are all acceptable options for
acute treatment
14. Icatibant may be particularly useful in enabling self-administration as intravenous access is not necessary
15. Regular prophylactic treatment with C1 inhibitor may be appropriate for patients requiring treatment for two or more attacks per week
16. Plasma-derived C1 inhibitor is the treatment of choice for acute attacks of HAE for children, pregnant and breast-feeding women, and those
trying to conceive
E: Dosing of C1 inhibitor
17. We recommend that patients use the licensed dose of C1 inhibitor. In certain circumstances, the dose may need adjustment according to
clinical response
18. A higher dose may be required if treatment is delayed. For early treatment via self administration, lower doses may be appropriate
19. If a second dose is needed, then the full dose will be required. It may therefore be a false economy to dose inappropriately low in the first
instance
F: Long-term prophylaxis
20. Evidence for the efficacy of anti-fibrinolytics is poor; however, a minority of patients may find them helpful
21. Attenuated androgens are effective in long-term prophylaxis for most people
22. The lowest effective dose of attenuated androgen should be used to minimize side effects
23. High doses of androgens may provoke severe side effects without added benefits
24. Doses of danazol above 200 mg daily should be exceptional
25. Doses of stanozolol above 4 mg daily should be exceptional
26. Treatment registries should be completed to allow better understanding of new products
27. Exceptionally, C1 inhibitor prophylaxis may be required when control of acute attacks is not possible by other means (including for children).
This should be reviewed at regular intervals
G: Treatment plans
28. All patients should have a treatment plan for acute and elective surgery, including dentistry
29. All patients should have an additional treatment plan in place to ensure their safety when away from home or abroad
30. Treatment plans should be developed according to individual need and updated regularly
H: Role of the specialist nurse
31. The specialist immunology nurse is pivotal in patient care
32. All patients should have timely access to a specialist immunology nurse
33. The specialist immunology nurse has a key role in supporting the patient and their family in the practicalities of living with HAE to achieve
the best quality of life
I: Patient support
34. Because HAE is a rare condition, patient information should be comprehensive and consistent
35. HAE patients benefit from direct contact with others with the same condition
36. Advocacy is important in ensuring equality of access and benefit
37. Patients may have inappropriately low expectations of QoL with HAE, which may limit their life options. This should be addressed
38. Patient information should be provided in an easily accessible and up-to-date format including electronic media
39. Specialist HAE patient support groups such as HAE UK have an important role in disseminating best practice in partnership with health care
professionals
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response rate. A statement about the role of progestagens as
long-term prophylaxis was not included in this document
because the relevant paper was not published at the time of
the steering group meeting.
The results also indicate strong consensus on aspects of
service organization and delivery, showing overwhelming
support for specialist services (statements 5–9), and
patient self-management and home therapy (statement
4). We welcome the principle of patient-centred, commu-
nity-based care, supported by easily accessible specialist
expertise and, where appropriate, local centres. The hae-
mophilia model of self-administration of intravenous
medications by patients and their families demonstrates
that this model is feasible and cost-effective. The net
financial effects of such an approach as applied to C1
inhibitor deficiency in the United Kingdom have not
been defined, but data from Denmark demonstrate the
benefits of the approach in reducing hospital attendance
and the burden of disease [48]. The results of the consen-
sus indicate clearly that both patients and health-care
workers endorse this model for C1 inhibitor deficiency, in
order to ensure that patients can achieve their full poten-
tial by early education and training in the prevention and
management of acute attacks.
Some important performance characteristics of the
Delphi method should be considered. The consensus
involves scientific evidence, but does not involve rigorous
review of scientific evidence in order to produce guid-
ance. This has produced a document that is complemen-
tary to existing guidelines from other bodies. It does not
seek to replicate or replace their work, but rather adds
another form of expert opinion evidence to the literature.
Compared to the generation of evidence-based guidelines
by small panels of experts, the Delphi method is more
inclusive and gathers opinion from a larger number of
professionals. The anonymity of respondents may temper
domination of the process by opinion leaders and encour-
ages free expression. However, the issue is not completely
resolved, as the question set is determined by a steering
group.
Another key difficulty is selection of the panel
members: a very inclusive process may produce an invalid
consensus by including responses from respondents who
lack expertise in the field, whereas an overly exclusive
process may not reflect a true consensus. We attempted
to engage with a wide variety of stakeholders outside the
clinical immunology and allergy community by collabo-
rating with relevant professional bodies, distributing
paper copies at professional meetings and permitting
peer-to-peer distribution of questionnaires. A significant
number of responses was obtained from outside the
immunology and allergy community which, in addition
to 51 responses from clinical immunologists and/or aller-
gists, is felt to capture the large majority of health-care
workers involved directly in the management of this dis-
ease. As these respondents work independently in special-
ist centres throughout the United Kingdom, we can be
confident that the remarkably high consensus does not
reflect training or service led by small number of opinion
leaders. However, it must be acknowledged that the UK
allergy and immunology community constitutes a small
group with a long-standing tradition of cooperation
through organizations such as UK PIN. In addition, the
methodology does not permit the calculation of a defined
response rate. Compared to the health-care worker data
set, results from patient respondents are less robust due
to relatively small numbers (n5 36) and the risk of ascer-
tainment bias.
The assumption that all participants are equal in terms
of knowledge and experience represents another weakness
of the methodology. This probably accounts for a rela-
tively high number of abstentions among respondents for
several more technical statements, notably 24, 25, 45 and
46. Finally, where successive rounds are utilized, the risk
is that the process may mould, rather than simply collate,
opinion; this was not a concern in this project, as consen-
sus was reached within a single round. Despite the short-
comings, the very high level of consensus among health-
care workers and a small sample of patients indicate
strong alignment of opinion.
This project has not addressed explicitly hereditary
bradykinin-mediated angioedema that is not related to
C1 inhibitor deficiency [49], but many of the statements
would be applicable to this group, whose specific needs
J: Commissioning
40. Central funding of HAE treatments will allow equality of access
41. Central funding of HAE treatments will allow affordability through a shared financial risk
42. A national approach to commissioning of HAE services enables accurate estimation of likely costs, based on mean resource utilization
43. Commissioning of home therapy will reduce utilization of hospital services
K: Children and adolescents
44. Children require exceptional treatment plans, which need to be developed according to individual need and updated regularly
45. The use of attenuated androgens should be avoided in pre-adolescent children
46. Tranexamic acid is the drug of choice for prophylaxis in children
47. Treatment registries should be completed to allow better understanding of unlicensed products
48. Treatment plans for children and adolescents should address planning for issues such as school trips and examinations
HAE5 hereditary angioedema; QoL5 quality of life
2014 UK HAE consensus
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Table 3. Respondents who publicly declare their support for the document.
Ms Karen Abrams, Specialist Nursing Practitioner in Immunology, Oxford University Hospitals NHS Trust
Dr Hana Alachkar, Consultant Immunologist, Salford Royal NHS Foundation Trust
Dr Peter Arkwright, Senior Lecturer and Honorary Consultant Paediatric Immunologist, University of Manchester
Dr Gururaj Arumugakani, Specialist Registrar in Immunology, Leeds Teaching Hospitals NHS Trust
Mrs Fran Ashworth, Clinical Nurse Specialist in Immunology, Sheffield Teaching Hospitals NHS Trust
Dr Amolak S Bansal, Consultant in Immunology and Allergy, Epsom and St Helier University Hospitals NHS Trust
Dr Claire Bethune, Consultant Immunologist, Plymouth Hospitals NHS Trust
Dr Malini Bhole, Consultant Immunologist, The Dudley Group NHS Foundation Trust
Dr Matthew Buckland, Consultant Immunologist, Barts Health NHS Trust, London
Dr Catherine Cale, Consultant Paediatric Immunologist, Great Ormond Street Hospital NHS Foundation Trust
Dr Anita Chandra, Clinical Immunologist, Cambridge University Hospitals NHS Foundation trust
Dr Ignatius Chua, Specialist Registrar in Immunology, Barts Health NHS Trust
Dr Sheila Clark, Consultant Dermatologist, Mid Yorkshire and Leeds Teaching Hospitals NHS Trusts
Professor Christopher Corrigan, Professor of Allergy, Asthma and Respiratory Science, Kings College London
Mr John Dempster, Immunology Nurse Specialist, Barts Health NHS Trust
Dr Tina A Dixon, Consultant Allergist, Royal Liverpool and Broadgreen University Hospital NHS Trust
Dr Philip Dore, Consultant Immunologist, Hull and East Yorkshire Hospitals NHS Trust
Dr Michael Duddridge, Consultant Clinical Immunologist, University Hospitals of Leicester NHS Trust
Dr David Edgar, Consultant Immunologist, The Royal Hospitals, Belfast
Dr Efrem Eren, Consultant Immunologist, University Hospital Southampton NHS Foundation Trust
Mrs Alex Farragher, Immunology Specialist Nurse,Central Manchester University Hospitals NHS Foundation Trust
Dr TJ Flood, Consultant in Paediatric Immunology, The Newcastle upon Tyne Hospitals NHS Trust
Dr Tomaz Pereira Garcez, Consultant Immunologist, Central Manchester University Hospitals NHS Foundation Trust
Dr Mark Gompels, Consultant Immunologist, North Bristol NHS Trust
Dr Clive Grattan, Consultant Dermatologist, Norfolk and Norwich Hospitals NHS Trust
Dr Elizabeth Griffiths, SpR in Allergy, Guys and St Thomas’s NHS Trust, London
Dr Sofia Grigoriadou, Consultant Immunologist, Barts Health NHS Trust
Professor Tim Harris, Professor of Emergency Medicine, Barts Health NHS Trust
Dr Grant Hayman, Consultant Clinical Immunologist, Epsom and St Helier University Hospitals NHS Trust
Dr Richard Herriot, Consultant Immunologist, Aberdeen Royal Infirmary
Dr Archana Herwadkar, Consultant Immunologist, Salford Royal NHS Foundation Trust
Dr Aarnood Huissoon, Consultant Immunologist, Heart of England NHS Foundation Trust
Dr Rashmi Jain, Consultant Immunologist, Oxford University Hospitals NHS Trust
Dr Stephen Jolles, Consultant Immunologist, University Hospital of Wales
Dr M Yousuf Karim, Consultant Immunologist, Frimley Park Hospitals NHS Foundation Trust andThe Royal Surrey County Hospital NHS
Foundation Trust
Dr DS Kumararatne Consultant Immunologist, Cambridge University Hospitals NHS Trust
Dr Hilary Longhurst, Consultant Immunologist, Barts Health NHS Trust
Ms Lorena Lorenzo, Immunology Specialist Nurse, Barts Health NHS Trust
Dr Joanna, Lukawska, Locum Consultant Allergist, Royal National Throat Nose and Ear Hospital
Dr John Maher, Senior Lecturer in Immunology and Honorary Consultant Immunologist, King’s College London
Miss Clare Malcolmson, Clinical Nurse Specialist in Immunology, Great Ormond Street Hospital NHS Foundation Trust
Dr Ania Manson, SpR in Clinical Immunology, Barts Health NHS Trust
Ms Gail Menzies, Immunology Nurse Specialist, Ninewells Hospital Dundee
Dr Joanne Miller, Specialist Registrar in Clinical Immunology, Oxford University Hospitals NHS Trust
Dr Vasantha Nagendran, Consultant Immunologist, Epsom and St Helier University Hospitals NHS Trust
Dr Iman Nasr, SpR in Immunology, Barts Health NHS Trust
Dr Sadia Noorani, Consultant Immunologist, Sandwell and West Birmingham NHS Trust
Dr D G Paige, Consultant Dermatologist, Barts Health NHS Trust, London
Dr Andrew Riordan, Consultant in Paediatric Infectious Diseases and Immunology, Alder Hey Children’s NHS Foundation Trust
Ms Carol Ross, Specialist Nursing Practitioner in Clinical Immunology, Oxford University Hospitals NHS Trust
Dr Sinisa Savic, Consultant Clinical Immunologist, Leeds Teaching Hospitals NHS Trust
Dr Suranjith Seneviratne, Consultant Immunologist, Royal Free London NHS Foundation Trust
Dr Ravishankar Sargur, Consultant Immunologist, Sheffield Teaching Hospitals NHS Foundation Trust
Dr Anna Shrimpton, Consultant Immunologist, Sheffield Teaching Hospitals NHS Foundation Trust
Mr Craig Simon, Immunology Nurse Specialist, Royal Liverpool and Broadgreen University Hospitals NHS Trust
Dr Catherine Stroud, Consultant Immunologist, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Mrs Christine Symons, Nurse Consultant in Immunology, Plymouth Hospitals NHS Trust
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are also addressed in a separate consensus document
[50]. Although the document is UK-centric, the themes
of quality improvement, patient-centred care and increas-
ing health-care costs are a focus and challenge for most
higher-income nations at the current time.
While responses are confidential and not individually
available to the steering committee, those responding
have been invited to support this paper publically. Sixty-
four of 91 health-care professionals indicated their pub-
licly declared support and are listed (Table 3) as the UK
2014 C1 Inhibitor Deficiency Consensus Group.
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